With the recent recognition of the importance of metabolic reprogramming in cancer progression, our study reveals a metabolic mechanism by which the bone microenvironment supports prostate cancer growth and survival, by up-regulation of G6PD, the rate-limiting enzyme of the PPP. The gene discussed is G6PD; the disease is prostate carcinoma.